ATE356223T1 - Gen und protein mit bezug zu hepatozellulärem karzinom - Google Patents

Gen und protein mit bezug zu hepatozellulärem karzinom

Info

Publication number
ATE356223T1
ATE356223T1 AT02765617T AT02765617T ATE356223T1 AT E356223 T1 ATE356223 T1 AT E356223T1 AT 02765617 T AT02765617 T AT 02765617T AT 02765617 T AT02765617 T AT 02765617T AT E356223 T1 ATE356223 T1 AT E356223T1
Authority
AT
Austria
Prior art keywords
gene
hepatocellular carcinoma
protein related
protein
domain
Prior art date
Application number
AT02765617T
Other languages
German (de)
English (en)
Inventor
Yusuke Nakamura
Yoichi Furukawa
Original Assignee
Japan President Univ Tokyo
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2399569 external-priority patent/CA2399569A1/en
Application filed by Japan President Univ Tokyo, Oncotherapy Science Inc filed Critical Japan President Univ Tokyo
Application granted granted Critical
Publication of ATE356223T1 publication Critical patent/ATE356223T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809Methods for determination or identification of nucleic acids involving differential detection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02765617T 2001-09-25 2002-09-25 Gen und protein mit bezug zu hepatozellulärem karzinom ATE356223T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32426101P 2001-09-25 2001-09-25
US39166602P 2002-06-26 2002-06-26
CA 2399569 CA2399569A1 (en) 2001-09-25 2002-08-23 Diagnostic markers and drug targets for treatment of cancer

Publications (1)

Publication Number Publication Date
ATE356223T1 true ATE356223T1 (de) 2007-03-15

Family

ID=27171637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02765617T ATE356223T1 (de) 2001-09-25 2002-09-25 Gen und protein mit bezug zu hepatozellulärem karzinom

Country Status (9)

Country Link
US (3) US7767392B2 (https=)
EP (1) EP1430152B1 (https=)
JP (1) JP4353798B2 (https=)
CN (1) CN1628179B (https=)
AT (1) ATE356223T1 (https=)
AU (1) AU2002329061A1 (https=)
DE (1) DE60218710T2 (https=)
ES (1) ES2283592T3 (https=)
WO (1) WO2003027143A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1628179B (zh) 2001-09-25 2011-04-20 肿瘤疗法科学股份有限公司 肝细胞癌的检测
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
DE602004032114D1 (de) * 2003-02-28 2011-05-19 Oncotherapy Science Inc Rna-interferenz für das gen znfn3a1 als verfahren zur hemmung des wachstums von krebszellen
CN1890382A (zh) * 2003-09-24 2007-01-03 肿瘤疗法科学股份有限公司 检测、诊断和治疗肝细胞癌(hcc)的方法
TWI350373B (en) * 2004-01-23 2011-10-11 Oncotherapy Science Inc Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
US20060189560A1 (en) * 2005-01-27 2006-08-24 Ajit Kumar Molecular method to augment RNA mediated gene silencing
WO2006092958A1 (en) * 2005-02-28 2006-09-08 Oncotherapy Science, Inc. Breast cancer related gene znfn3a1
WO2006121208A1 (en) * 2005-05-12 2006-11-16 Oncotherapy Science, Inc. Polymorphisms of the e2f-1 binding element and methods of determining cancer susceptibility
TW200741009A (en) * 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
EP2171082B1 (en) 2007-06-14 2012-11-28 Oncotherapy Science, Inc. Methods of identifying agents that modulate methylation of vegfr1 by smyd3
CN102356316B (zh) 2009-03-05 2015-07-08 独立行政法人产业技术综合研究所 肝内胆管癌的检出、辨别方法
WO2011011366A2 (en) * 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
EP2785870B1 (en) 2011-12-02 2017-05-03 OncoTherapy Science, Inc. Smyd2 as a target gene for cancer therapy and diagnosis
WO2014141652A1 (en) * 2013-03-11 2014-09-18 Oncotherapy Science, Inc. Smyd3 peptides and vaccines containing the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039200A1 (en) 1998-01-29 1999-08-05 Thomas Jefferson University Molecular markers for diagnosing hepatocellular carcinoma
US6783961B1 (en) 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
WO2000017355A2 (en) 1998-09-18 2000-03-30 Incyte Pharmaceuticals, Inc. Human cytoskeleton associated proteins
JP2003521231A (ja) * 1999-01-29 2003-07-15 インサイト・ファーマスーティカルズ・インコーポレイテッド 核酸結合タンパク質
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
WO2001029221A2 (en) 1999-10-20 2001-04-26 Zymogenetics, Inc. Proteins and polynucleotides encoding them
AU783762B2 (en) 1999-12-23 2005-12-01 Arca Biopharma, Inc. Methods and materials relating to prothrombinase-like polypeptides and polynucleotides
EP1591448A3 (en) 2000-04-18 2006-01-11 Nuvelo, Inc. Novel nucleic acids and polypeptides
JP2005503760A (ja) 2001-01-24 2005-02-10 プロテイン デザイン ラブス, インコーポレイテッド 乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法
GB0111218D0 (en) 2001-05-08 2001-06-27 Cancer Res Ventures Ltd Assays methods and means
US6989245B2 (en) 2001-05-11 2006-01-24 The Burnham Institute Screening, diagnostic and therapeutic methods relating to RIZ
DK2280070T3 (en) 2001-07-23 2015-08-24 Univ Leland Stanford Junior Methods and compositions for use in RNAi-mediated inhibition of gene expression in mammals
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
CN1628179B (zh) * 2001-09-25 2011-04-20 肿瘤疗法科学股份有限公司 肝细胞癌的检测
US8003315B2 (en) * 2001-12-13 2011-08-23 Exelixis, Inc. TAOJIKs as modifiers of the beta-catenin pathway and methods of use
DE602004032114D1 (de) 2003-02-28 2011-05-19 Oncotherapy Science Inc Rna-interferenz für das gen znfn3a1 als verfahren zur hemmung des wachstums von krebszellen
TWI350373B (en) 2004-01-23 2011-10-11 Oncotherapy Science Inc Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
WO2006092958A1 (en) 2005-02-28 2006-09-08 Oncotherapy Science, Inc. Breast cancer related gene znfn3a1
TW200741009A (en) 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
EP2171082B1 (en) 2007-06-14 2012-11-28 Oncotherapy Science, Inc. Methods of identifying agents that modulate methylation of vegfr1 by smyd3

Also Published As

Publication number Publication date
WO2003027143A3 (en) 2003-10-30
US20040235018A1 (en) 2004-11-25
JP4353798B2 (ja) 2009-10-28
CN1628179B (zh) 2011-04-20
WO2003027143A2 (en) 2003-04-03
DE60218710D1 (de) 2007-04-19
AU2002329061A1 (en) 2003-04-07
US7767392B2 (en) 2010-08-03
EP1430152A2 (en) 2004-06-23
US20120149762A1 (en) 2012-06-14
EP1430152B1 (en) 2007-03-07
US8148080B2 (en) 2012-04-03
US20100248240A1 (en) 2010-09-30
DE60218710T2 (de) 2007-12-06
CN1628179A (zh) 2005-06-15
JP2005511023A (ja) 2005-04-28
ES2283592T3 (es) 2007-11-01

Similar Documents

Publication Publication Date Title
DE60218710D1 (de) Gen und protein mit bezug zu hepatozellulärem karzinom
ATE402188T1 (de) Bindungsproteine als biosensoren
DE50306809D1 (de) Verwendung von nativem zein zur verbesserung des haarzustandes und mittel
LTPA2015049I1 (lt) Žpv 45 l1 optimizuota ekspresija mielėse
EP2230319A3 (en) Gene expression markers for breast cancer prognosis
EA200700213A1 (ru) Терапевтические композиции с нейротоксином ботулина
ATE530911T1 (de) Bindungsproteine als biosensoren
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
HUE044812T2 (hu) Prolinspecifikus endoproteázok alkalmazása peptidek és fehérjék hidrolízisére
MY139031A (en) Vaccine composition comprising virus-like particles of human papillomavirus
ATE518960T1 (de) Gentechnisch hergestellte zinkfingerproteine zur regulation der genexpression
IL199414A0 (en) Thrombospondin fragments and uses thereof in clinical assays for cancer and generation of antibodies and other binding agents
WO2005044792A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
ATE445402T1 (de) Neue verwendung von pde5-hemmern
SE0302304D0 (sv) Novel compounds
SI1546182T1 (sl) Sestavki in postopki za diagnozo in zdravljenje tumorja
DE60101559D1 (de) Benutzung von comt-inhibitoren als analgetika
ATE513040T1 (de) Zinkfingerdomänenbibliotheken
ATE527377T1 (de) Erstellung von genexpressionprofilen aus ffpe- proben
DE60230194D1 (de) Therapeutische verwendung von mitgliedern der n,n-dicylcohexyl-2-hydroxy-7,7-dimethylbicycloä2.2.1ühept-1-ylmethanesulphonamide-familie
SG147469A1 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
DE60201337D1 (de) Kontinuierliche umesterung von alkoxysilanen
DE50212649D1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
WO2004006864A3 (en) Methods and compositions for the enhancement of wound healing
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties